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Abstract 
The incidence of diabetes and rate of obesity is on the rise, along with the use of 
organophosphorus insecticides in the United States. Organophosphates (OP), a specific class of 
pesticide that is biodegradable and readily available for purchase, represent 50% of all 
insecticides used worldwide.1 OPs are toxic and can cause numerous acute effects, but the health 
effects from low dose chronic exposure have not been thoroughly investigated. Interestingly, 
there have been few studies showing a correlation between the rise in organophosphate pesticide 
use and the elevated rates of diabetes and obesity.2 These correlations should be more thoroughly 
investigated however the current methods of detection for OPs in human plasma use a time- and 
cost-consuming sample preparation method, which do not always yield accurate results. Thus, 
the need to develop and validate a sensitive, selective, and high-throughput analytical method for 
the accurate and precise determination of organophosphate levels in human plasma. 
A simple “dilute and shoot” sample preparation has been developed along with an ultra-
performance liquid chromatography coupled with mass spectrometry (UPLC-MS) method for 
 
detection and quantification of OPs in blood plasma. The method was validated and standard 
curves have been generated revealing the limits of detection and quantification to range from 
0.0660 ng/mL to 19.1 ng/mL and 0.200 ng/mL to 58.0 ng/mL respectively. The percent 
accuracies ranged from 0 to 262% for all organophosphates. Several patients showed detectable 
levels of diazinon, malathion, and terbufos. Interestingly, these patients were either obese or 
obese/diabetic. One obese and diabetic patient displayed both a detectable and quantifiable levels 
of diazinon (0.237 ng/mL), which had a limit of detection and quantification of 0.0660 and 0.200 
ng/mL respectively. These results suggest that more intensive studies should be conducted on 
larger population of patients.  
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Chapter 1: Introduction 
 
1.1 Pesticides 
Pesticides are any substance or mixture of substances intended for preventing, destroying, 
repelling, or mitigating any pest.3 There are many different classes of pesticides, including 
herbicides, algaecides, fungicides, insecticides, etc. Each class of pesticide is used to target a 
specific pest group; for example insecticides are used to target insects. Approximately 1.1 billion 




Organophosphorus insecticides or organophosphates (OPs) comprise a specific class of 
pesticide that is biodegradable and readily available for purchase. Insecticides represent 18% of 
all pesticide use worldwide and are responsible for 5% of pesticide use in the United States.4 The 
Environmental Protection Agency reported in 2012 that about 20 million pounds of 
organophosphorus insecticides were used in the United States.4 In addition to the widespread use 
in the agricultural industry, organophosphates are commonly used every day to eradicate 
household pests such as insects, rats, mice, and weeds. Some of the most commonly used OPs 




Figure 1: Structure for chlorpyrifos and diazinon 
 
Chlorpyrifos is toxic to humans and exposure has been linked to various neurological 
issues and autoimmune disorders.5 Due to these exposure effects, chlorpyrifos has almost been 
removed completely from commercial household products and is solely used in the agricultural 
industry. A map depicting the estimated use of chlorpyrifos in 2013 is shown in Figure 2.6 Areas 
of heavy usage include the Midwest and South Eastern United States where farming is prevalent.  
Diazinon, an insecticide used in both indoor and outdoor commercial pest control, was used in 
the United States until was also outlawed in commercial household products in 2004 due to its 
toxicity.7 Diazinon is one of the few OPs that have significant lipid solubility, which allows for 




Figure 2: A map of the United States depicting estimated 
agricultural use of chlorpyrifos in 2013.6 
 
1.3 Exposure 
 The main routes of exposure to OPs are oral, dermal, and/or inhalation. Human exposure 
can occur occupationally, from drift, and/or ingestion from contaminated food stuffs. 
 
1.3.1 Oral 
 The general population is exposed to organophosphates through the ingestion of food 
and/or drinking water. The Environmental Protection Agency (EPA) has tolerance limits for 
residues of organophosphates to prevent adverse health effects. These limits vary depending on 






 Dermal exposure occurs when handling organophosphates during either the 
manufacturing or application process. Dermal exposure can be varied, depending on the carrier 
solvent. Absorption is higher when acetone is used as a solvent compared to water. Uptake is 
also dependent on the hydration and temperature of the skin.9 
 
1.3.3 Inhalation 
 Inhalation of organophosphates occurs when the pesticide is administered using sprays, 
mists, and powders. Pesticide applicators for example can be exposed to OPs by inhalation if not 
wearing proper equipment. Inhalation exposure is typically combined with exposure to the eyes 
and mucous membranes. Recently more than 50 farm workers were exposed to a pesticide drift 
in Bakersfield, California. Twelve people reported symptoms of vomiting and nausea. The active 
ingredient in the insecticide was chlorpyrifos, which can cause severe neurotoxic symptoms if 
touched, inhaled, or ingested.10  
 
1.4 Toxicity 
 The toxicity of organophosphates is largely due to the inhibition of acetylcholinesterase 
by the oxon form of the OPs. Acetylcholinesterase is used to break down acetylcholine into 
acetate and choline. The oxon form of OPs are converted from organophosphates by cytochrome 
p-450. Other toxicities, however, aside from acetylcholinesterase inhibition have been studied. 
These include oxidative stress, delayed neurotoxicity via inhibition of NTE, mitochondrial 




1.4.1 Cytochrome P-450 
 Cytochrome P-450s are a family of more than 50 enzymes that are essential for the 
metabolism of many toxicants and drugs. Cytochrome P-450 is predominantly expressed in the 
liver. Upon ingestion, organophosphates are transported to the liver through the blood stream and 
then metabolized in the liver by different isoforms of cytochrome P-450 and its esterase 
enzymes. These enzymes are known to convert OPs to their respective oxon, diethylphosphate 
and diethylthiophosphate metabolites (Figure 3).11 
 
 





1.4.2 Inhibition of Acetylcholinesterase 
 These metabolites exert their toxicity by inhibiting various enzymes in the cell. The oxon 
metabolite is particularly toxic because it inhibits acetylcholinesterase, an enzyme responsible 
for converting acetylcholine to choline and acetate (Figure 4).12-13 An increase in the amount of 
acetylcholine in the body causes continuous stimulation of the muscles, glands, and central 
nervous system which can result in a variety of neurological issues and, ultimately, fatal 
convulsions.  
 
Figure 4: Acetylcholinesterase enzyme function. The top scheme represents 
normal acetylcholinesterase activity. The bottom scheme represents inhibition of 




1.4.3 Acute and Chronic Effects 
Acute OP poisoning causes a cholinergic crisis, which results in salivation, lacrimation, 
urination, diarrhea, gastrointestinal distress, and emesis. Symptoms can also include headaches, 
muscle twitching, nausea, tachycardia, and seizures. Acute effects have been heavily studied, 
while chronic effects have not. The long term or chronic effects from organophosphate poisoning 
are just recently being investigated. Neurological deficits are observed after chronic exposure to 
organophosphates due to the inhibition of acetylcholinesterase.12 Chronic low dose 
organophosphate exposure has also been linked to the incidence of diabetes and obesity in 
animal and human models.14-17  
A health study conducted from 1993 to 2003 showed licensed pesticide applicators in 
Iowa and North Carolina who had been exposed to insecticides had an increased risk of 
developing diabetes. Specifically, seven organophosphates chlorpyrifos, coumaphos, diazinon, 
dichlorvos, phorate, terbufos, and trichlorfon, showed increased odds of developing diabetes.16  
Slotkin and coworkers reported in 2010 that neonatal rats who were given chlorpyrifos, 
diazinon, and parathion developed metabolic dysfunction which resembled prediabetes.17 In 
adulthood, the rats consumed a high fat diet that led to an excessive amount of weight gain. 
Results of the study concluded that early-life exposure to organophosphates leads to metabolic 
dysfunction and a defective central nervous system that could lead to diabetes and obesity 






Figure 5: How early-life exposure to OPs could contribute to obesity and diabetes. 
Adapted from Figure 1 in “Does early-life exposure to organophosphate insecticides 
lead to prediabetes and obesity?”17  
 
 Currently, it is unknown how OPs contribute to the development of diabetes. Some 
studies, however, suggest that OPs interact with acetylcholinesterase and cause downstream 
toxic effects that result in a diabetic state. Type 2 diabetes is a combination of insulin resistance 
and β-cell dysfunction. β-cells are located in the islet, which is located in the pancreas. 
Pancreatic β-cells contain M3-muscarinic receptors (acetylcholine receptors) that are responsible 
for regulating insulin homeostasis (Figure 6). One hypothesis is when organophosphates inhibit 
acetylcholinesterase, causing a buildup of acetylcholine in the body. The abundance of 
acetylcholine floods the M3-muscarinic receptor causing an increase of insulin to be released. 
This causes the body to become accustomed to the high amount of insulin. The abundance of 
acetylcholine eventually causes the M3-muscarinic receptor to shut down, therefore causing beta 
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cell dysfunction. The body has become used to the high amount of insulin causing insulin 
resistance. The beta cells are no longer able to release the amount of insulin needed and the body 
is used to a high amount of insulin, therefore the amount of insulin that is released from the beta 




Figure 6: Cartoon depiction of the pancreas. The first panel shows the basic makeup of the 
pancreas. The second panel shows the makeup of an islet. The third panel shows the β-cell 
function in regard to producing insulin.18 
 
1.5 Diabetes and Obesity 
Fourteen states, including North Carolina, compose a geographic area referred to as the 
“diabetes belt” (Figure 7). 19 North Carolina has approximately 12% prevalence of diabetes, 
which is higher than the national average of 9.3%.20 The diagnosis of obesity and diabetes has 
significantly increased from 1994 to 2013 as shown in Figure 8A and 8B. When comparing 
Figures 2 and 8, there appears to be a correlation between the states with higher percentages of 
diagnosed diabetes and obesity and the states with heavy pesticide usage. However, Figure 2 is 
10 
 
only of the pesticide of chlorpyrifos, so you must take into account the location of the pesticide 
use and other lifestyle factors. The correlation between diabetes, obesity, and organophosphates 
needs to be studied further to see if there is causal relationship and to understand the role 
organophosphates play in disease pathways. Due to the health effects caused by 
organophosphates, it is crucial to develop rapid and sensitive analytical techniques to test for OP 
exposure. Current analytical methods rely on liquid-liquid extractions and solid-phase 
extractions to isolate organophosphates.9,22-23 These sample preparation methods take time and 
depend on numerous factors such as compound polarity and volatility. Therefore, a simpler and 
less time-consuming sample preparation method needs to be developed. It is therefore the goal of 
this study to develop and validate a method that meets the above criteria and to test the method 
on plasma samples that have been collected from actual patients. The overarching goal of the 




Figure 7: A map from 2013 highlighting the states that 
comprise the "diabetes belt”.  The region spans 15 states and 





Figure 8: A) A comparison of the diagnosis of diabetes in the United States (1994, 
2000, and 2013). Data reveal an increase in the incidences of diabetes from 1994 to 
2013.21 B) A comparison of the diagnosis of obesity in the United States (1994, 2000, 
and 2013). Data reveal an increase in the incidences of diabetes from 1994 to 2013.21 
 
 
Chapter 2: Instrumental Methods 
 
2.1 Previous Methods Used to Detect Organophosphates in Plasma 
 Organophosphate analysis is typically performed using solid phase extraction or liquid-
liquid extraction followed by gas chromatography mass spectrometry or liquid chromatography 
mass spectrometry. Barr and coworkers analyzed 29 pesticides in human plasma of which 6 were 
the OPs of interest in this study. The method employed solid phase extraction followed by gas 
chromatography mass spectrometry. They achieved limits of detection (LOD) from 0.5 to 12 
parts per trillion (ppt). Although the LODs were low, the percent recoveries for the spiked 
human plasma only ranged from 14 to 27%.24 A different study conducted by Tarbah analyzed 
23 OPs in human serum, 2 of which coincided with the organophosphates of interest in this 
study. The method employed a liquid-liquid extraction followed by gas chromatography mass 
spectrometry. The percent recoveries for the spiked human serum ranged from 50 to 133% of 
spiked human serum.1 A study conducted by Musshoff analyzed 22 organophosphates in human 
whole blood, 4 of which were the OPs of interest in this study. The method employed solid phase 
micro extraction followed by gas chromatography mass spectrometry. The LODs ranged from 
0.01 to 0.10 ppt. Although the LODs were low, the percent recoveries for the human whole 
blood were also low and ranged from only 0.1 to 19.6%.25 
 
2.2 Dilute & Shoot 
 The main concept of the dilute & shoot sample preparation method is essentially diluting 
the sample and then injecting it into the UPLC-MS. The method is simple to employ and cost 
efficient. Its of the method saves sample preparation time and therefore reduces the overall 
13 
 
amount of time spent on the experiment. Reducing the overall time spent on the experiment also 
reduces the cost, compared to other sample preparation methods like solid phase and liquid-
liquid extractions which require more time. 
 
2.3 UPLC-MS 
Ultra-performance liquid chromatography (UPLC) is a relatively new technique that is 
furthering the possibilities in liquid chromatography.26 UPLC is similar to high-performance 
liquid chromatography (HPLC) in that it uses high pressure and a column to separate analytes. 
These analytes are then identified by either absorbance, mass to charge ratio, or counts per 
second depending on the detection method available. However, while HPLC columns contain 
particles with sizes ranging from 2 to 5 μm and maximum pressures around 6000 psi (~400 barr), 
UPLC systems are specially designed to use columns with particle sizes below 1.2 μm and 
maximum operating pressures of 15,000 psi (~1000 barr).23 The smaller particle size and 
increased pressures result in better resolution, speed, and sensitivity.27  UPLC has many 
advantages over traditional HPLC, such as increased sensitivity, using smaller volumes of 
solvents, and higher throughput due to its shorter elution time. The latter factors can result in 




Chapter 3: Method Validation & Results 
3.1 Method Overview 
 As previously mentioned, a simple dilute and shoot method was chosen for sample 
preparation along with UPLC-MS for sample analysis. Stock solutions were prepared along with 
spiking solutions, standards, and matrix standards. Once prepared the samples were injected into 
the UPLC-MS.  
 
3.2 Validation 
 Validation involves the collection and evaluation of data, from beginning to the end of an 
experiment, that provides scientific evidence the process or method is consistently effective in 
yielding production quality results. Validation is necessary to prove a method is precise, 
accurate, and produces quality results. In this study, a mini validation occurred compared to a 
full-scale validation. The mini validation consisted of running a set of solvent and matrix 





 Chlorpyrifos, coumaphos, diazinon, dichlorvos, dichlorvos-d6, formic acid, malathion, 
terbufos, and trichlorfon were obtained from Sigma-Aldrich. The acetonitrile was received EMD 
Chemicals. The DI water came the onsite Hydro Picosystem. The UPLC-MS/MS was a Waters 




3.3.2 Internal Standard, Mobile Phases, and Strong & Weak Wash Solution Preparation 
 The internal standard (IS) dichlorvos-d6 in acetonitrile (ACN), was prepared by weighing 
dichlorvos-d6 (0.000134g) into a 100 mL volumetric flask and diluting to volume with ACN 
giving a concentration of 1200 ng/mL. Mobile Phase A (MP A) 0.1% formic acid (FA) in 95/5 
water/ACN was prepared by adding 1.0 mL FA, 950.0 mL DI Water, and 50.0 mL ACN to a 
mobile phase bottle and mixed using a magnetic stirrer. Mobile phase B 0.1% FA in 5/95 
water/ACN was prepared by adding 1.0 mL FA, 50.0 mL DI water, and 950.0 mL ACN to a 
mobile phase bottle and mixed using a magnetic stirrer. The strong wash 0.1% FA in ACN was 
prepared by adding 500.0 μL FA and 500.0 mL ACN to a mobile phase bottle and mixed using a 
magnetic stirrer. The weak wash 80/20 water/ACN was prepared by adding 400.0 mL water and 
100.0 mL ACN to a mobile phase bottle and mixed using a magnetic stirrer. 
 
3.3.3 Preparation of Stock Solutions 
Solvent stock solutions were prepared for each organophosphate by weighing an allotted 
amount into either a 50-mL volumetric flask or scintillation vial (Table 1). The solutions were 
diluted to volume with acetonitrile and then mixed by inversion.  
 












Chlorpyrifos 2.5 10.23 ✓ ✓ 4.09 
Coumaphos 50 4.92 ✓ ✓ 0.0984 
Diazinon 50 5.25 ✓ ✓ 0.105 
Dichlorvos 50 6.85 ✓ ✓ 0.137 
Malathion 50 4.89 ✓ ✓ 0.0977 
Phorate 50 5.45 ✓ ✓ 0.109 
Terbufos 50 11.15 ✓ ✓ 0.223 
Trichlorfon 2.5 9.53 ✓ ✓ 3.81 
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3.3.4 Spiking Solutions Preparation 
 A 1000x ng/mL spiking solution stock was prepared by transferring aliquots of each 
organophosphate to a scintillation vial, adding acetonitrile (0.025 mL), and finally vortexing the 
solution briefly (Table 2). The spiking solutions with concentration factors ranging from 0.75x 
to 500x ng/mL were made through serial dilution by transferring a solution aliquot to a 
scintillation vial, diluting with acetonitrile, and vortexing briefly (Table 3). 
 
 
Table 2: Spiking Solution Stock Preparation (SA) (~1000x ng/mL). A Specific 
Aliquot of Each OP was Pipetted into a Scintillation Vial, the Solution was 













Chlorpyrifos 4.09 0.25 
✓ ✓ 
102000 
Coumaphos 0.0984 2.8 27600 
Diazinon 0.105 0.075 788 
Dichlorvos 0.137 2.0 27400 
Malathion 0.0977 1.2 11700 
Phorate 0.109 2.6 28300 
Terbufos 0.223 0.8 17800 





Table 3: Preparation of Spiking Solutions (~0.75x to 500x ng/mL). Eight Spiking Solutions 
were Made by Serial Dilution Starting with the Spiking Solution Stock, then Aliquoting a 



















SA 1000x -- -- -- -- -- 
SA1 500x 1000x 0.5 0.5 1.0 ✓ 
SA2 250x 500x 0.5 0.5 1.0 ✓ 
SA3 100x 250x 0.4 0.6 1.0 ✓ 
SA4 25x 100x 0.25 0.75 1.0 ✓ 
SA5 10x 25x 0.4 0.6 1.0 ✓ 
SA6 2.5x 10x 0.25 0.75 1.0 ✓ 
SA7 x 2.5x 0.4 0.6 1.0 ✓ 
SA8 0.75x 2.5x 0.3 0.7 1.0 ✓ 
 
 
3.3.5 Preparation of Standards 
 The solvent standards were prepared by spiking DI water with the previously made 
spiking solutions and adding the internal standard and acetonitrile into a 1.5 mL centrifuge tube 
and briefly vortexing. The solutions were then centrifuged for 10 minutes at 14000 rpm and 9°C. 
The supernatants were transferred to limited volume inserts in autosampler vials, mobile phase A 































SStd1 500x SA1 ✓ ✓ ✓ ✓ ✓ ✓
SStd2 250x SA2 ✓ ✓ ✓ ✓ ✓ ✓
SStd3 100x SA3 ✓ ✓ ✓ ✓ ✓ ✓
SStd4 25x SA4 ✓ ✓ ✓ ✓ ✓ ✓
SStd5 10x SA5 ✓ ✓ ✓ ✓ ✓ ✓
SStd6 2.5x SA6 ✓ ✓ ✓ ✓ ✓ ✓
SStd7 x SA7 ✓ ✓ ✓ ✓ ✓ ✓
SStd8 0.75x SA8 ✓ ✓ ✓ ✓ ✓ ✓
ISa 
SBLK 0x ACN ✓ ACN ✓ ✓ ✓ ✓ ✓
SBLK 0x ACN ✓ ACN ✓ ACN ✓ ✓ ✓ ✓
a. Internal Standard. 
b. Solutions were vortexed after this step. 
c. Solutions were centrifuged at 14,000 rpm for 10 minutes (9 °C) after this step. 
 
3.3.6 Preparation of Matrix Standards 
 Matrix standards were prepared the same way as the solvent standards shown in Table 4. 
The only difference between the solvent and matrix is the matrix uses plasma instead of water. 
The matrix standards were made using rat plasma and then human plasma. 
 
3.3.7 Instrument Parameters 
 A Waters Acquity UPLC/Applied Biosystems 4000 QTrap was used as the UPLC-MS 
system. A Waters Acquity UPLC BEH Phenyl column (2.1 x 100mm, 1.7 μm) was used. The 
mobile phase A was 0.1% formic acid in 95/5 water/ACN and mobile phase B was 0.1% formic 
19 
 
acid in 5/95 water/ACN. The gradient started at 90% A and 10% B for 5 minutes, switched to 
0% A and 100% B for 2 minutes, and then back to 90% A and 10% B for 2 minutes for a total 
run time of 9 minutes. The flow rate was 0.5 mL/min. The column and autosampler temperatures 
were 25°C and 10°C respectively. The injection volume was 5 μL. The ionization mode was ESI 
and was in positive mode. The data system used was AB Sciex Analyst 1.6.2. 
 
3.4 Results 
 The data from the solvent and matrix standards that were run by Jen Gilliam, an analyst 
art RTI International, were used to prove that the dilute & shoot method was suitable to use for 
the analysis of OP levels in human plasma. Figure 9 illustrates the solvent and matrix standards 
for chlorpyrifos and diazinon with highlighted correlation coefficients. The percent accuracies 





Figure 9: Solvent and matrix standards for chlorpyrifos and diazinon. Solvent standard is DI 
water and the matrix is human plasma. 
 














SA5 MA6 Chlorpyrifos 255 63.8 252 63.4 98.8 99.3 
SA7 MA3 Coumaphos 6.9 690 6.87 681 99.5 98.7 
SA4 MA2 Diazinon 4.93 49.3 4.85 48.7 98.3 98.7 
SA4 MA1 Dichlorvos 171 3430 171 3350 100 97.7 
SA4 MA2 Malathion 73.1 731 72.7 718 99.4 98.3 
SA5 MA2 Phorate 70.8 1780 70.8 1750 100 98.3 
SA1 MA3 Terbufos 2230 445 2220 421 99.4 94.7 
SA7 MA7 Trichlorfon 23.9 23.9 23.4 23.6 98 98.5 
 
Chapter 4: Application of the Validated Method to the Study Samples 
 
4.1 Application of Validated Method 
 The validated method was applied to the study samples previously collected. The internal 
standards, mobile phases, stock solutions, spiking solutions, and standards were remade for the 
application of the validated method. The human study samples were then prepared. Once 





 Chlorpyrifos, coumaphos, dichlorvos, dichlorvos-d6, formic acid, malathion, terbufos, 
and trichlorfon were obtained from Sigma-Aldrich. Diazinon was obtained from Chem-Service. 
The acetonitrile was received EMD Chemicals. The DI water came the onsite Hydro Picosystem. 
The human plasma study samples were collected from patients in Greenville, North Carolina. 
The UPLC-MS/MS was a Waters Acquity UPLC/Applied Biosystem 4000 QTrap. The column 
was a Waters Acquity BEH 1.7μm Phenyl column. 
 
4.2.2 Human Study Samples 
 Volunteers for the study were recruited from East Carolina University Physicians 
Bariatric Clinic and Eastern Physical Medicine & Rehabilitation. Patient recruitment was done in 
accordance to UMCIRB 015-000984. Patients were chosen and put into the following categories: 
obese non-diabetic, obese diabetic, and lean. The patients were considered obese if they had a 
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body mass index over 30.0. A total of 45 patients were recruited, 15 for each category. Five to 
six mL of blood was collected into vacutainer test tubes containing K2-EDTA. The tubes were 
inverted 8 times, put on ice for 15 minutes, and then centrifuged at 2500 rpm for 12 minutes. The 
plasma was then aliquoted into 1.5 mL microcentrifuge tubes and stored in a -80°C freezer 
immediately.  
 
4.2.3 Internal Standard, Mobile Phases, and Strong & Weak Wash Solution Preparation 
 The internal standard (IS) dichlorvos-d6 in acetonitrile (ACN), was prepared by weighing 
dichlorvos-d6 (0.000134g) into a 100 mL volumetric flask and diluting to volume with ACN 
giving a concentration of 1200 ng/mL. Mobile Phase A (MP A) 0.1% formic acid (FA) in 95/5 
water/ACN was prepared by adding 1.0 mL FA, 950.0 mL DI Water, and 50.0 mL ACN to a 
mobile phase bottle and mixed using a magnetic stirrer. Mobile phase B 0.1% FA in 5/95 
water/ACN was prepared by adding 1.0 mL FA, 50.0 mL DI water, and 950.0 mL ACN to a 
mobile phase bottle and mixed using a magnetic stirrer. The strong wash 0.1% FA in ACN was 
prepared by adding 500.0 μL FA and 500.0 mL ACN to a mobile phase bottle and mixed using a 
magnetic stirrer. The weak wash 80/20 water/ACN was prepared by adding 400.0 mL water and 
100.0 mL ACN to a mobile phase bottle and mixed using a magnetic stirrer. 
4.2.4 Preparation of Stock Solutions 
Solvent stock solutions were prepared for each organophosphate by weighing an allotted 
amount into either a 50-mL volumetric flask or scintillation vial (Table 6). The solutions were 


















Chlorpyrifos 2.5 10.24 ✓ ✓ 4.10 
Coumaphos 50 4.88 ✓ ✓ 0.0976 
Diazinon 50 5.83 ✓ ✓ 0.117 
Dichlorvos 50 7.71 ✓ ✓ 0.154 
Malathion 50 5.43 ✓ ✓ 0.109 
Phorate 50 5.74 ✓ ✓ 0.115 
Terbufos 50 12.98 ✓ ✓ 0.260 
Trichlorfon 2.5 9.66 ✓ ✓ 3.86 
 
 
4.2.5 Spiking Solutions Preparation 
 A 1000x ng/mL spiking solution stock was prepared by transferring aliquots of each 
organophosphate to a scintillation vial, adding acetonitrile (0.025 mL), and vortexing the 
solution briefly (Table 7). The spiking solutions with concentration factors ranging from 0.75x 
to 500x ng/mL were made through a serial dilution by transferring a solution aliquot to a 








Table 7: Spiking Solution Stock Preparation (SA) (~1000x ng/mL). A specific 
Aliquot of Each OP was Pipetted into a Scintillation Vial, the Solution was 













Chlorpyrifos 4.10 0.25 
✓ ✓ 
102500 
Coumaphos 0.0976 2.8 27300 
Diazinon 0.117 0.075 878 
Dichlorvos 0.154 2.0 30800 
Malathion 0.109 1.2 13100 
Phorate 0.115 2.6 29900 
Terbufos 0.260 0.8 20800 
Trichlorfon 3.86 0.25 96500 
 
 
4.2.6 Preparation of Standards 
 The solvent standards were prepared by spiking DI water with the previously made 
spiking solutions and adding the internal standard and acetonitrile to a 1.5 mL centrifuge tube 
followed by vortexing briefly. The solutions were then centrifuged for 10 minutes at 14000 rpm 
and 9°C. The supernatants were transferred to limited volume inserts in autosampler vials, 
mobile phase A (MPA) was added, and the standards were vortexed briefly (Table 4). 
 
4.2.7 Preparation of Human Study Samples 
 The study samples (human plasma) were prepared the same way as the solvent standards 
shown in Table 4. The study samples were aliquoted instead of water and an additional 25 μL of 




4.2.8 Instrument Parameters 
 A Waters Acquity UPLC/Applied Biosystems 4000 QTrap was used as the UPLC-MS 
system. A Waters Acquity UPLC BEH Phenyl column (2.1 x 100mm, 1.7 μm) was used. The 
mobile phase A was 0.1% formic acid in 95/5 water/ACN and mobile phase B was 0.1% formic 
acid in 5/95 water/ACN. The gradient started at 90% A and 10% B for 5 minutes, switched to 
0% A and 100% B for 2 minutes, and then back to 90% A and 10% B for 2 minutes for a total 
run time of 9 minutes. The flow rate was 0.5 mL/min. The column and autosampler temperatures 
were 25°C and 10°C respectively. The injection volume was 10 μL. The ionization mode was 
ESI and was in positive mode. The data system used was AB Sciex Analyst 1.6.2. 
 
4.3 Generation of Calibration Curves and Limits of Detection & Quantification 
Determination 
Table 8 displays the solvent standard information used to construct the calibration curves 
for chlorpyrifos and diazinon in Figure 10. The calibration curves were used to calculate the 
linear equations with a 1/x weighting. The linear equations were then used to determine the OP 











Table 8: Solvent Standards Chlorpyrifos & Diazinon Analyte 















SStd8 19.2 3.59×103 3.06×105 1.17×10-2 
SStd7 25.6 7.37×103 3.38×105 2.18×10-2 
SStd6 64.1 1.45×104 2.69×105 5.40×10-2 
SStd5 256 4.19×104 2.51×105 1.67×10-1 
SStd4 641 1.57×105 3.12×105 5.05×10-1 
SStd3 2560 4.14×105 2.85×105 1.45 
SStd2 6410 1.01×106 3.12×105 3.25 
SStd1 12800 2.07×106 3.19×105 6.48 
Diazinon 
SStd8 0.165 1.52×103 3.06×105 4.95×10-3 
SStd7 0.22 2.23×103 3.38×105 6.60×10-3 
SStd6 0.549 3.66×103 2.69×105 1.36×10-2 
SStd5 2.2 1.08×104 2.51×105 4.30×10-2 
SStd4 5.49 3.49×104 3.12×105 1.12×10-1 
SStd3 22 7.79×104 2.85×105 2.73×10-1 
SStd2 54.9 2.41×105 3.12×105 7.71×10-1 
SStd1 110 5.72×105 3.19×105 1.79 




Figure 10: Solvent standards chlorpyrifos & diazinon with a 1/x weighting. 
 
The limit of detection (LOD) is the lowest analyte concentration that can be reliably 
distinguished from the limit of blank (LOB). The limit of quantification (LOQ) is the lowest 
concentration that can reliably detected. The LOD can be calculated a few different ways such as 
the following: 
𝐿𝑂𝐷 = 𝐿𝑂𝐵 + 1.645(𝑆𝐷)     Eq. 1 
𝐿𝑂𝐷 = 𝑀𝑒𝑎𝑛 𝑏𝑙𝑎𝑛𝑘 + 3.3×𝑆𝐷 𝑏𝑙𝑎𝑛𝑘    Eq. 2 
    𝐿𝑂𝐷 = 3.3×
𝜎
𝑆
           Eq. 3 
 
SD is the standard deviation of a low concentration sample. SD blank is the standard deviation of 
the blank. Sigma is shown below in equation 4 and S is the slope of the linear regression. 
𝜎 =  √
1
(𝑛 −2)
[∑(𝑦 − ?̅?)2 −
[∑(𝑥−?̅?)(𝑦−?̅?)]2
∑(𝑥−?̅?)




N is the sample size. X and Y are the known x and y values. X and Y bar are the averages of the 
known x and ys. Equation 3 will be used to determine the LOD for this study. The LOQ can also 
be determined a few different ways as well: 
 





       Eq. 6 
 
Equation 6 will be used to determine the LOQ for this study. The LOD and LOQ for each 
organophosphate is shown below in Table 9. 
 
 
Table 9: The Limit of Detection and Quantification of Each 
Organophosphate. Sigma is the Standard Error of x and y. S is the Slope of the 
Linear Regression. 
OP σ S LOD (ng/mL) LOQ 
(ng/mL) 
Chlorpyrifos 0.00302 0.0005204 19.1 58.0 
Coumaphos 0.00360 0.003543 3.36 10.2 
Diazinon 0.000306 0.01528 0.0660 0.200 
Dichlorvos 0.00249 0.001162 7.07 21.4 
Malathion 0.00114 0.004151 0.908 2.75 
Phorate 0.00150 0.0004734 10.5 31.7 
Terbufos 0.000433 0.001321 1.08 3.28 




Chapter 5: Results & Discussion 
 
5.1 Solvent Standard Results 
 The solvent standards for each organophosphate showed promising results. Each 
calibration curve had a high correlation coefficient, suggesting linearity. Figure 11 illustrates the 
solvent standards for chlorpyrifos and diazinon with highlighted correlation coefficients. The 
percent accuracies for each standard and organophosphate were determined. Table 10 gives the 
percent accuracies for each of the standards for chlorpyrifos and diazinon. The percent accuracy 
is calculated using the following equation: 
 
% 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =  








×100   Eq. 7 
 
The correlation coefficients and percent accuracies prove that the dilute & shoot method is 
suitable for analysis of organophosphates in human plasma. The linear equations generated from 
the calibration curves were then used to determine the concentrations of the organophosphates in 





Figure 11: Solvent standards for chlorpyrifos and diazinon with a 1/x weighting. 
 
Table 10: Percent Accuracy for Each Solvent Standard for Chlorpyrifos and Diazinon. 
Sample 






(ng/mL) Accuracy (%) 
SStd8 Chlorpyrifos Diazinon 19.2 0.165 2.78 0.0988 14.5 59.9 
SStd7 Chlorpyrifos Diazinon 25.6 0.22 22.1 0.207 86.1 93.9 
SStd6 Chlorpyrifos Diazinon 64.1 0.549 84.1 0.666 131 121 
SStd5 Chlorpyrifos Diazinon 256 2.2 301 2.59 118 118 
SStd4 Chlorpyrifos Diazinon 641 5.49 950 7.09 148 129 
SStd3 Chlorpyrifos Diazinon 2560 22 2770 17.7 108 80.3 
SStd2 Chlorpyrifos Diazinon 6410 54.9 6220 50.2 97.1 91.5 
SStd1 Chlorpyrifos Diazinon 12800 110 12400 117 97.1 106 
 
 
5.2 Study Sample Results 
 Each of the 45 patient samples were run through the UPLC-MS and yielded interesting 
results. The only organophosphates detected in any of the study samples were diazinon, 
malathion, and terbufos. The patients that had any OP levels detected belonged to the obese or 
31 
 
obese-diabetic category. There were no lean patients that had any detectable OP levels. Tables 
11 through 14 give the calculated concentration organophosphate levels and the patient category.  
 
Table 11: Patients with an Instrument Response to Diazinon 
and their Patient Category. 
Diazinon 




OPHM 8 0.0215 Obese 
OPHM 9 0.0506 Obese 
OPHM 10 0.0339 Obese Diabetic 
OPHM 36 0.0188 Obese 
OPHM 37 0.237 Obese Diabetic 
OPHM 40 0.048 Obese 
OPHM 1 No Peak - 






Table 12: Patients with an Instrument Response to 
Malathion and their Patient Category. 
Malathion 





OPHM 9 0.522 Obese 
OPHM 37 2.41 Obese Diabetic 





Table 13: Patients with an Instrument Response to 
Terbufos and their Patient Category. 
Terbufos 




OPHM 8 0.0507 Obese 
OPHM 9 0.0588 Obese 
OPHM 37 2.49 Obese Diabetic 
OPHM 38 0.141 Obese Diabetic 
OPHM 40 0.628 Obese 




Table 14: All other patients that did not Show an Instrument 
Response to OPs or the Levels were Below Zero 
Chlorpyrifos, Coumaphos, Dichlorvos, Phorate, & Trichlorfon 





Dichlorvos OPHM 18 < 0 - 






All Others No Peaks - 
 
 
5.3 Discussion of Results 
 Many the study samples did not yield any peaks for any of the organophosphates, but a 
few samples did such as OPHM 37. The study sample OPHM 37 had peaks for the 
organophosphates diazinon, malathion, and terbufos. The calculated concentration in nanograms 
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per milliliter were 0.237, 2.41, and 2.49 respectively. The concentration for diazinon was above 
the LOD (0.0660) and LOQ (0.200), while the concentrations for malathion and terbufos were 
above the LOD (0.908 & 1.08), but below the LOQ (2.75 & 3.28). This study sample came from 
a patient who is an obese-diabetic. The study samples that gave an instrument response and 
concentrations were all from patients who are obese or obese-diabetics, no lean patients had any 
detectable levels of organophosphates. This could possibly help assess the possible correlation 
that organophosphates could be a factor in causing obesity and diabetes. To further help this 
assessment it would be best to look at lowering the concentration range, looking at the 
metabolites of the organophosphates, and to have a larger population to sample . If the 
organophosphates weren’t detected, that doesn’t mean the patient was not exposed to OPs.  
These organophosphates could have been present and metabolized. Overall the results gave some 
detectable organophosphate levels in human plasma that could help establish the association 
between OP levels and obesity and diabetes. 
  
 
Chapter 6: Future Goals 
 
6.1 Lower Concentration Range 
 One future direction would be to lower the concentration range of the organophosphates. 
The calculated concentrations from the study samples were much lower than 0.75x concentration 
factor, which was the smallest concentration factor in range of concentration factors. Lowering 
the overall concentrations of organophosphates in the solvent standards would provide a more 
accurate calibration curve, since it would be more tailored to the OP levels that were detected in 
this study.  
 
6.2 Metabolites 
 As mentioned in the discussion of results, just because OP levels were not detected does 
not mean the metabolites of these organophosphates are not in the human body. One possible 
experiment would to be measure the OP metabolites levels in human plasma. The experiment 
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Appendix A: Validation 
Table A15: Solvent & Matrix Standards Concentrations by Concentration Factors (ng/mL) 
OP 500x 250x 100x 25x 10x 2.5x x 0.75x 
Chlorpyrifos 12800 6380 2550 638 255 63.8 25.1 19.1 
Coumaphos 3450 1730 690 173 69.0 17.3 6.90 5.18 
Diazinon 98.5 49.3 19.7 4.93 1.97 0.493 0.197 0.148 
Dichlorvos 3430 1710 685 171 68.5 17.1 6.85 5.15 
Malathion 1460 731 293 73.1 29.3 7.31 2.93 2.20 
Phorate 3550 1780 708 178 70.8 17.8 7.08 5.33 
Terbufos 2230 1110 445 111 44.5 11.1 4.45 3.35 
Trichlorfon 11900 5980 2390 598 239 59.8 23.9 17.9 
 
 
Table A16: Solvent Standards Chlorpyrifos Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 19.1 1.15E+03 3.46E+04 3.31E-02 18.3 96 
SA7 25.5 1.69E+03 4.27E+04 3.95E-02 24.3 95.2 
SA6 63.8 3.30E+03 3.76E+04 8.78E-02 68.6 108 
SA5 255 1.18E+04 4.10E+04 2.87E-01 252 98.8 
SA4 638 3.32E+04 4.54E+04 7.32E-01 661 104 
SA3 2550 1.04E+05 3.80E+04 2.73E+00 2500 98.1 
SA2 6380 2.76E+05 3.92E+04 7.04E+00 6450 101 
SA1 12800 5.58E+05 4.02E+04 1.39E+01 12800 99.6 





Figure A12: Solvent standards for chlorpyrifos with a 1/x weighting. 
 
 
Table A17: Solvent Standards Coumaphos Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 5.18 1.09E+03 3.46E+04 3.16E-02 5.37 104 
SA7 6.9 1.56E+03 4.27E+04 3.65E-02 6.87 99.5 
SA6 17.3 2.33E+03 3.76E+04 6.20E-02 14.7 84.9 
SA5 69 1.05E+04 4.10E+04 2.57E-01 74.3 108 
SA4 173 2.69E+04 4.54E+04 5.93E-01 177 102 
SA3 690 8.49E+04 3.80E+04 2.23E+00 679 98.4 
SA2 1730 2.37E+05 3.92E+04 6.04E+00 1850 107 
SA1 3450 4.39E+05 4.02E+04 1.09E+01 3340 96.8 
a. Internal standard is dichlorvos d-6 
 
y = 0.00109 +0.0131 








































Figure A13: Solvent standards for coumaphos with a 1/x weighting. 
 
 
Table A18: Solvent Standards Diazinon Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 0.148 7.49E+02 3.46E+04 2.16E-02 0.137 92.3 
SA7 0.197 1.17E+03 4.27E+04 2.74E-02 0.187 94.9 
SA6 0.493 2.49E+03 3.76E+04 6.61E-02 0.525 107 
SA5 1.97 9.81E+03 4.10E+04 2.39E-01 2.04 103 
SA4 4.93 2.54E+04 4.54E+04 5.60E-01 4.85 98.3 
SA3 19.7 8.87E+04 3.80E+04 2.33E+00 20.4 103 
SA2 49.3 2.30E+05 3.92E+04 5.85E+00 51.1 104 
SA1 98.5 4.41E+05 4.02E+04 1.10E+01 96 97.5 
a. Internal standard is dichlorvos d-6 
 
 







































Figure A14: Solvent standards for diazinon with a 1/x weighting. 
 
 
Table A19: Solvent Standards Dichlorvos Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 5.15 7.75E+02 3.46E+04 2.24E-02 2.76 53.6 
SA7 6.85 1.47E+03 4.27E+04 3.43E-02 6.54 95.5 
SA6 17.1 2.56E+03 3.76E+04 6.80E-02 17.2 101 
SA5 68.5 9.71E+03 4.10E+04 2.36E-01 70.5 103 
SA4 171 2.52E+04 4.54E+04 5.55E-01 171 100 
SA3 685 8.18E+04 3.80E+04 2.15E+00 677 98.8 
SA2 1710 2.20E+05 3.92E+04 5.62E+00 1770 104 
SA1 3430 4.29E+05 4.02E+04 1.07E+01 3370 98.3 
a. Internal standard is dichlorvos d-6 
 







































Figure A15: Solvent standards for dichlorvos with a 1/x weighting. 
 
Table A20: Solvent Standards Malathion Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 2.2 9.18E+02 3.46E+04 2.65E-02 2.24 102 
SA7 2.93 1.36E+03 4.27E+04 3.17E-02 2.87 98.1 
SA6 7.31 2.39E+03 3.76E+04 6.36E-02 6.72 92 
SA5 29.3 1.07E+04 4.10E+04 2.61E-01 30.6 104 
SA4 73.1 2.76E+04 4.54E+04 6.09E-01 72.7 99.4 
SA3 293 9.51E+04 3.80E+04 2.50E+00 302 103 
SA2 731 2.46E+05 3.92E+04 6.28E+00 759 104 
SA1 1460 4.73E+05 4.02E+04 1.18E+01 1420 97.5 
a. Internal standard is dichlorvos d-6 
 







































Figure A16: Solvent standards for malathion with a 1/x weighting 
 
Table A21: Solvent Standards Phorate Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 5.33 6.89E+02 3.46E+04 1.99E-02 5.51 103 
SA7 7.08 8.48E+02 4.27E+04 1.98E-02 5.49 77.6 
SA6 17.8 2.69E+03 3.76E+04 7.14E-02 21.9 123 
SA5 70.8 9.25E+03 4.10E+04 2.25E-01 70.8 100 
SA4 178 2.55E+04 4.54E+04 5.61E-01 177 99.7 
SA3 708 8.29E+04 3.80E+04 2.18E+00 693 97.9 
SA2 1780 2.14E+05 3.92E+04 5.44E+00 1730 97.2 
SA1 3550 4.57E+05 4.02E+04 1.14E+01 3610 102 
a. Internal standard is dichlorvos d-6 
 








































Figure A17: Solvent standards for phorate with a 1/x weighting 
 
Table A22: Solvent Standards Terbufos Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 3.35 6.43E+02 3.46E+04 1.86E-02 2.88 85.8 
SA7 4.45 1.32E+03 4.27E+04 3.10E-02 5.12 115 
SA6 11.1 2.29E+03 3.76E+04 6.08E-02 10.5 94.8 
SA5 44.5 1.08E+04 4.10E+04 2.62E-01 47 106 
SA4 111 2.74E+04 4.54E+04 6.04E-01 109 98.1 
SA3 445 9.38E+04 3.80E+04 2.47E+00 446 100 
SA2 1110 2.44E+05 3.92E+04 6.21E+00 1120 101 
SA1 2230 4.92E+05 4.02E+04 1.22E+01 2220 99.4 
a. Internal standard is dichlorvos d-6 
 
 







































Figure A18: Solvent standards for terbufos with a 1/x weighting 
 
 
Table A23: Solvent Standards Trichlorfon Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 17.9 1.09E+03 3.46E+04 3.15E-02 16.1 90.1 
SA7 23.9 1.72E+03 4.27E+04 4.01E-02 23.4 98 
SA6 59.8 3.17E+03 3.76E+04 8.41E-02 60.5 101 
SA5 239 1.24E+04 4.10E+04 3.02E-01 244 102 
SA4 598 3.37E+04 4.54E+04 7.42E-01 615 103 
SA3 2390 1.15E+05 3.80E+04 3.02E+00 2530 106 
SA2 5980 2.84E+05 3.92E+04 7.24E+00 6100 102 
SA1 11900 5.54E+05 4.02E+04 1.38E+01 11600 97.6 
a. Internal standard is dichlorvos d-6 
 





















































y = 0.00119 + 0.0124 







































Table A24: Matrix Standards Chlorpyrifos Analyte Concentrations (ng/mL), Area Ratio, 






















MA8-1 19.1 1.16E+03 3.82E+04 3.03E-02 19.8 104 
MA8-2 19.1 8.95E+02 3.66E+04 2.44E-02 14.6 76.5 
MA8-3 19.1 1.05E+03 3.83E+04 2.74E-02 17.2 90.3 
MA8-4 19.1 1.11E+06 4.15E+04 2.67E+01 23500 123000 
MA8-5 19.1 6.18E+03 3.31E+04 1.87E-01 158 826 
MA8-6 19.1 2.52E+03 5.37E+04 4.69E-02 34.4 180 
MA7 25.5 1.53E+03 4.27E+04 3.58E-02 24.6 96.6 
MA6 63.8 2.88E+03 3.61E+04 7.98E-02 63.4 99.3 
MA5 255 1.38E+04 4.43E+04 3.12E-01 268 105 
MA4 638 2.59E+02 3.40E+03 7.62E-02 60.2 9.44 
MA3 2550 1.16E+05 4.11E+04 2.83E+00 2480 97.3 
MA2 6380 2.59E+05 3.74E+04 6.91E+00 6080 95.3 
MA1 12800 7.63E+05 5.10E+04 1.49E+01 13200 103 





























































Table A25: Matrix Standards Coumaphos Analyte Concentrations (ng/mL), Area Ratio, 






















MA8-1 5.18 9.31E+02 3.82E+04 2.44E-02 5.25 101 
MA8-2 5.18 1.02E+03 3.66E+04 2.78E-02 6.26 121 
MA8-3 5.18 1.04E+03 3.83E+04 2.72E-02 6.09 118 
MA8-4 5.18 9.56E+02 4.15E+04 2.31E-02 4.86 93.9 
MA8-5 5.18 7.93E+02 3.31E+04 2.40E-02 5.14 99.2 
MA8-6 5.18 1.37E+03 5.37E+04 2.55E-02 5.59 108 
MA7 6.9 1.44E+03 4.27E+04 3.36E-02 7.97 116 
MA6 17.3 2.05E+03 3.61E+04 5.67E-02 14.8 85.3 
MA5 69 1.08E+04 4.43E+04 2.43E-01 69.5 101 
MA4 173 2.57E+02 3.40E+03 7.57E-02 20.3 11.8 
MA3 690 9.54E+04 4.11E+04 2.32E+00 681 98.7 
MA2 1730 2.12E+05 3.74E+04 5.67E+00 1670 96.3 
MA1 3450 6.12E+05 5.10E+04 1.20E+01 3520 102 





























































Table A26: Matrix Standards Diazinon Analyte Concentrations (ng/mL), Area Ratio, 






















MA8-1 0.148 6.58E+02 3.82E+04 1.72E-02 0.138 93.5 
MA8-2 0.148 7.86E+02 3.66E+04 2.15E-02 0.176 119 
MA8-3 0.148 9.20E+02 3.83E+04 2.40E-02 0.198 134 
MA8-4 0.148 9.90E+02 4.15E+04 2.39E-02 0.197 133 
MA8-5 0.148 8.36E+02 3.31E+04 2.53E-02 0.209 141 
MA8-6 0.148 1.28E+03 5.37E+04 2.38E-02 0.197 133 
MA7 0.197 9.88E+02 4.27E+04 2.31E-02 0.19 96.5 
MA6 0.493 2.12E+03 3.61E+04 5.88E-02 0.503 102 
MA5 1.97 1.08E+04 4.43E+04 2.43E-01 2.12 108 
MA4 4.93 6.26E+02 3.40E+03 1.84E-01 1.61 32.6 
MA3 19.7 9.33E+04 4.11E+04 2.27E+00 19.9 101 
MA2 49.3 2.07E+05 3.74E+04 5.54E+00 48.7 98.7 
MA1 98.5 5.74E+05 5.10E+04 1.12E+01 98.8 100 





























































Table A27: Matrix Standards Dichlorvos Analyte Concentrations (ng/mL), Area Ratio, 






















MA8-1 5.15 1.33E+03 3.82E+04 3.47E-02 4.36 84.6 
MA8-2 5.15 1.32E+03 3.66E+04 3.61E-02 4.68 90.9 
MA8-3 5.15 1.29E+03 3.83E+04 3.38E-02 4.13 80.3 
MA8-4 5.15 1.52E+03 4.15E+04 3.66E-02 4.81 93.4 
MA8-5 5.15 1.20E+03 3.31E+04 3.62E-02 4.7 91.3 
MA8-6 5.15 1.74E+03 5.37E+04 3.23E-02 3.77 73.3 
MA7 6.85 1.77E+03 4.27E+04 4.14E-02 5.96 87.1 
MA6 17.1 3.46E+03 3.61E+04 9.59E-02 19.2 112 
MA5 68.5 1.42E+04 4.43E+04 3.22E-01 73.9 108 
MA4 171 2.58E+03 3.40E+03 7.61E-01 180 106 
MA3 685 1.19E+05 4.11E+04 2.91E+00 701 102 
MA2 1710 2.72E+05 3.74E+04 7.27E+00 1760 103 
MA1 3430 7.06E+05 5.10E+04 1.38E+01 3350 97.7 



























































Table A28: Matrix Standards Malathion Analyte Concentrations (ng/mL), Area Ratio, 






















MA8-1 2.2 8.62E+02 3.82E+04 2.26E-02 2.26 103 
MA8-2 2.2 8.81E+02 3.66E+04 2.41E-02 2.45 111 
MA8-3 2.2 9.81E+02 3.83E+04 2.56E-02 2.65 120 
MA8-4 2.2 9.39E+02 4.15E+04 2.27E-02 2.27 103 
MA8-5 2.2 6.62E+02 3.31E+04 2.00E-02 1.93 87.8 
MA8-6 2.2 1.12E+03 5.37E+04 2.09E-02 2.04 92.7 
MA7 2.93 1.20E+03 4.27E+04 2.81E-02 2.97 101 
MA6 7.31 2.34E+03 3.61E+04 6.48E-02 7.64 104 
MA5 29.3 9.80E+03 4.43E+04 2.21E-01 27.6 94.2 
MA4 73.1 7.41E+02 3.40E+03 2.18E-01 27.2 37.2 
MA3 293 9.27E+04 4.11E+04 2.26E+00 287 97.9 
MA2 731 2.11E+05 3.74E+04 5.64E+00 718 98.3 
MA1 1460 5.93E+05 5.10E+04 1.16E+01 1480 101 



























































Table A29: Matrix Standards Phorate Analyte Concentrations (ng/mL), Area Ratio, 






















MA8-1 5.33 8.54E+02 3.82E+04 2.24E-02 5.64 106 
MA8-2 5.33 7.74E+02 3.66E+04 2.11E-02 5.29 99.2 
MA8-3 5.33 8.44E+02 3.83E+04 2.21E-02 5.55 104 
MA8-4 5.33 8.51E+02 4.15E+04 2.05E-02 5.11 95.9 
MA8-5 5.33 6.28E+02 3.31E+04 1.90E-02 4.67 87.6 
MA8-6 5.33 1.18E+03 5.37E+04 2.20E-02 5.54 104 
MA7 7.08 1.25E+03 4.27E+04 2.92E-02 7.58 107 
MA6 17.8 2.22E+03 3.61E+04 6.16E-02 16.9 94.8 
MA5 70.8 1.08E+04 4.43E+04 2.45E-01 69.3 97.8 
MA4 178 2.99E+02 3.40E+03 8.80E-02 24.4 13.7 
MA3 708 9.58E+04 4.11E+04 2.33E+00 667 94.2 
MA2 1780 2.29E+05 3.74E+04 6.11E+00 1750 98.3 
MA1 3550 6.46E+05 5.10E+04 1.27E+01 3620 102 
























































Table A30: Matrix Standards Terbufos Analyte Concentrations (ng/mL), Area Ratio, 






















MA8-1 3.35 9.77E+02 3.82E+04 2.56E-02 4.1 122 
MA8-2 3.35 7.20E+02 3.66E+04 1.97E-02 3.14 93.9 
MA8-3 3.35 9.98E+02 3.83E+04 2.61E-02 4.19 125 
MA8-4 3.35 9.71E+02 4.15E+04 2.34E-02 3.75 112 
MA8-5 3.35 9.26E+02 3.31E+04 2.80E-02 4.49 134 
MA8-6 3.35 1.45E+03 5.37E+04 2.71E-02 4.35 130 
MA7 4.45 1.07E+03 4.27E+04 2.51E-02 4.03 90.5 
MA6 11.1 2.52E+03 3.61E+04 6.97E-02 11.2 101 
MA5 44.5 1.15E+04 4.43E+04 2.59E-01 41.8 93.9 
MA4 111 2.11E+02 3.40E+03 6.23E-02 10 9.04 
MA3 445 1.07E+05 4.11E+04 2.61E+00 421 94.7 
MA2 1110 2.37E+05 3.74E+04 6.33E+00 1020 92.2 
MA1 2230 7.39E+05 5.10E+04 1.45E+01 2340 105 






























































Table A31: Matrix Standards Trichlorfon Analyte Concentrations (ng/mL), Area Ratio, 






















MA8-1 17.9 1.05E+03 3.82E+04 2.74E-02 17.4 97 
MA8-2 17.9 1.10E+03 3.66E+04 3.00E-02 19.6 109 
MA8-3 17.9 9.16E+02 3.83E+04 2.39E-02 14.4 80.6 
MA8-4 17.9 9.34E+02 4.15E+04 2.25E-02 13.2 73.9 
MA8-5 17.9 9.14E+02 3.31E+04 2.76E-02 17.6 98.2 
MA8-6 17.9 1.29E+03 5.37E+04 2.40E-02 14.5 80.7 
MA7 23.9 1.48E+03 4.27E+04 3.47E-02 23.6 98.5 
MA6 59.8 2.76E+03 3.61E+04 7.63E-02 58.9 98.5 
MA5 239 1.33E+04 4.43E+04 3.00E-01 249 104 
MA4 598 3.08E+03 3.40E+03 9.07E-01 765 128 
MA3 2390 1.14E+05 4.11E+04 2.77E+00 2340 98.1 
MA2 5980 2.81E+05 3.74E+04 7.50E+00 6370 106 
MA1 11900 6.94E+05 5.10E+04 1.36E+01 11500 97.1 


























































Appendix B: Application of Validated Method 
Table B32: Solvent Standards Concentrations by Concentration Factors (ng/mL) 
OP 500x 250x 100x 25x 10x 2.5x x 0.75x 
Chlorpyrifos 12800 6410 2560 641 256 64.1 25.6 19.2 
Coumaphos 3410 1710 683 171 68.3 17.1 6.83 5.12 
Diazinon 110 54.9 22.0 5.49 2.20 0.549 0.220 0.165 
Dichlorvos 3850 1930 770 193 77.0 19.3 7.70 5.78 
Malathion 1640 819 328 81.9 32.8 8.19 3.28 2.46 
Phorate 3740 1870 748 187 74.8 18.7 7.48 5.61 
Terbufos 2600 1300 520 130 52.0 13.0 5.20 3.90 
Trichlorfon 12100 6030 2410 603 241 60.3 24.1 18.1 
 
 
Table B33: Solvent Standards Chlorpyrifos Analyte Concentrations (ng/mL), Area Ratio, 






















SStd8 19.2 3.59E+03 3.06E+05 1.17E-02 2.78 14.5 
SStd7 25.6 7.37E+03 3.38E+05 2.18E-02 22.1 86.1 
SStd6 64.1 1.45E+04 2.69E+05 5.40E-02 84.1 131 
SStd5 256 4.19E+04 2.51E+05 1.67E-01 301 118 
SStd4 641 1.57E+05 3.12E+05 5.05E-01 950 148 
SStd3 2560 4.14E+05 2.85E+05 1.45E+00 2770 108 
SStd2 6410 1.01E+06 3.12E+05 3.25E+00 6220 97.1 
SStd1 12800 2.07E+06 3.19E+05 6.48E+00 12400 97.1 






Figure B28: Solvent standards for chlorpyrifos with a 1/x weighting. 
 
 
Table B34: Solvent Standards Coumaphos Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 5.12 4.80E+03 3.06E+05 1.57E-02 3.35 65.5 
SA7 6.83 9.85E+03 3.38E+05 2.91E-02 7.14 105 
SA6 17.1 2.05E+04 2.69E+05 7.62E-02 20.4 120 
SA5 68.3 6.56E+04 2.51E+05 2.62E-01 72.8 107 
SA4 171 2.34E+05 3.12E+05 7.50E-01 211 123 
SA3 683 5.51E+05 2.85E+05 1.93E+00 544 79.7 
SA2 1710 1.83E+06 3.12E+05 5.86E+00 1650 96.7 
SA1 3410 4.03E+06 3.19E+05 1.26E+01 3560 104 












































Figure B29: Solvent standards for coumaphos with a 1/x weighting. 
 
 
Table B35: Solvent Standards Diazinon Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 0.165 1.52E+03 3.06E+05 4.95E-03 0.0988 59.9 
SA7 0.22 2.23E+03 3.38E+05 6.60E-03 0.207 93.9 
SA6 0.549 3.66E+03 2.69E+05 1.36E-02 0.666 121 
SA5 2.2 1.08E+04 2.51E+05 4.30E-02 2.59 118 
SA4 5.49 3.49E+04 3.12E+05 1.12E-01 7.09 129 
SA3 22 7.79E+04 2.85E+05 2.73E-01 17.7 80.3 
SA2 54.9 2.41E+05 3.12E+05 7.71E-01 50.2 91.5 
SA1 110 5.72E+05 3.19E+05 1.79E+00 117 106 












































Figure B30: Solvent standards for diazinon with a 1/x weighting. 
 
Table B36: Solvent Standards Dichlorvos Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 5.78 7.78E+03 3.06E+05 2.54E-02 < 0 N/A 
SA7 7.7 1.08E+04 3.38E+05 3.20E-02 < 0 N/A 
SA6 19.3 2.55E+04 2.69E+05 9.50E-02 50.6 262 
SA5 77 6.14E+04 2.51E+05 2.45E-01 180 233 
SA4 193 1.67E+05 3.12E+05 5.37E-01 431 223 
SA3 770 2.75E+05 2.85E+05 9.65E-01 800 104 
SA2 1930 6.38E+05 3.12E+05 2.04E+00 1730 89.5 
SA1 3850 1.37E+06 3.19E+05 4.31E+00 3680 95.5 
a. Internal standard is dichlorvos d-6 
 











































Figure B31: Solvent standards for dichlorvos with a 1/x weighting. 
 
Table B37: Solvent Standards Malathion Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 2.46 8.67E+03 3.06E+05 2.83E-02 1.6 65.2 
SA7 3.28 1.18E+04 3.38E+05 3.48E-02 3.16 96.4 
SA6 8.19 1.69E+04 2.69E+05 6.30E-02 9.94 121 
SA5 32.8 4.10E+04 2.51E+05 1.63E-01 34.2 104 
SA4 81.9 1.47E+05 3.12E+05 4.72E-01 108 132 
SA3 328 3.18E+05 2.85E+05 1.11E+00 263 80.3 
SA2 819 1.02E+06 3.12E+05 3.28E+00 785 95.8 
SA1 1640 2.27E+06 3.19E+05 7.12E+00 1710 104 















































Figure B32: Solvent standards for malathion with a 1/x weighting. 
 
Table B38: Solvent Standards Phorate Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 5.61 8.25E+02 3.06E+05 2.70E-03 0.99 17.6 
SA7 7.48 2.15E+03 3.38E+05 6.36E-03 8.72 117 
SA6 18.7 3.87E+03 2.69E+05 1.44E-02 25.7 138 
SA5 74.8 1.07E+04 2.51E+05 4.25E-02 85.1 114 
SA4 187 3.68E+04 3.12E+05 1.18E-01 245 131 
SA3 748 9.12E+04 2.85E+05 3.20E-01 671 89.7 
SA2 1870 2.42E+05 3.12E+05 7.77E-01 1640 87.6 
SA1 3740 6.02E+05 3.19E+05 1.89E+00 3980 106 













































Figure B33: Solvent standards for phorate with a 1/x weighting. 
 
Table B39: Solvent Standards Terbufos Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 3.9 2.66E+03 3.06E+05 8.68E-03 2.6 66.8 
SA7 5.2 3.99E+03 3.38E+05 1.18E-02 4.96 95.4 
SA6 13 7.11E+03 2.69E+05 2.65E-02 16.1 124 
SA5 52 2.20E+04 2.51E+05 8.76E-02 62.3 120 
SA4 130 6.06E+04 3.12E+05 1.94E-01 143 110 
SA3 520 1.69E+05 2.85E+05 5.93E-01 445 85.6 
SA2 1300 5.03E+05 3.12E+05 1.61E+00 1220 93.6 
SA1 2600 1.15E+06 3.19E+05 3.61E+00 2730 105 










































Figure B34: Solvent standards for terbufos with a 1/x weighting. 
 
Table B40: Solvent Standards Trichlorfon Analyte Concentrations (ng/mL), Area Ratio, 






















SA8 18.1 0.00E+00 3.06E+05 0.00E+00 No Peak 0 
SA7 24.1 0.00E+00 3.38E+05 0.00E+00 No Peak 0 
SA6 60.3 3.19E+03 2.69E+05 1.19E-02 87.8 146 
SA5 241 1.38E+04 2.51E+05 5.52E-02 184 76.2 
SA4 603 7.41E+04 3.12E+05 2.38E-01 588 97.5 
SA3 2410 2.45E+05 2.85E+05 8.61E-01 1970 81.6 
SA2 6030 7.59E+05 3.12E+05 2.43E+00 5450 90.3 
SA1 12100 1.89E+06 3.19E+05 5.92E+00 13200 109 

































































































Appendix C: Chromatograms 
















Appendix D: Instrumental Parameters 
 Instrumental Parameters are attached as a supplemental file. 
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